AR062229A1 - Uso de antagonistras del receptor de glucocorticoides para el tratamiento de estados infecciosos - Google Patents
Uso de antagonistras del receptor de glucocorticoides para el tratamiento de estados infecciososInfo
- Publication number
- AR062229A1 AR062229A1 ARP070103470A ARP070103470A AR062229A1 AR 062229 A1 AR062229 A1 AR 062229A1 AR P070103470 A ARP070103470 A AR P070103470A AR P070103470 A ARP070103470 A AR P070103470A AR 062229 A1 AR062229 A1 AR 062229A1
- Authority
- AR
- Argentina
- Prior art keywords
- glucocorticoid receptor
- mammalian subject
- treatment
- receptor antagonists
- receptor antagonist
- Prior art date
Links
- 239000003850 glucocorticoid receptor antagonist Substances 0.000 title abstract 3
- 208000015181 infectious disease Diseases 0.000 title abstract 3
- 230000002458 infectious effect Effects 0.000 title abstract 2
- CZWCKYRVOZZJNM-USOAJAOKSA-N dehydroepiandrosterone sulfate Chemical compound C1[C@@H](OS(O)(=O)=O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 CZWCKYRVOZZJNM-USOAJAOKSA-N 0.000 abstract 2
- 229940126013 glucocorticoid receptor antagonist Drugs 0.000 abstract 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 abstract 2
- 210000002966 serum Anatomy 0.000 abstract 2
- DBLOJPKZEOYNBN-SQNIBIBYSA-N (8s,13s,14s)-13-methyl-2,6,7,8,11,12,14,15,16,17-decahydro-1h-cyclopenta[a]phenanthren-3-one Chemical compound C1CC2=CC(=O)CCC2=C2[C@@H]1[C@@H]1CCC[C@@]1(C)CC2 DBLOJPKZEOYNBN-SQNIBIBYSA-N 0.000 abstract 1
- -1 1,3-benzodioxol- 5-yl Chemical group 0.000 abstract 1
- 125000000530 1-propynyl group Chemical group [H]C([H])([H])C#C* 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229960000890 hydrocortisone Drugs 0.000 abstract 1
- 230000003308 immunostimulating effect Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 229960003248 mifepristone Drugs 0.000 abstract 1
- VKHAHZOOUSRJNA-GCNJZUOMSA-N mifepristone Chemical compound C1([C@@H]2C3=C4CCC(=O)C=C4CC[C@H]3[C@@H]3CC[C@@]([C@]3(C2)C)(O)C#CC)=CC=C(N(C)C)C=C1 VKHAHZOOUSRJNA-GCNJZUOMSA-N 0.000 abstract 1
- 210000000440 neutrophil Anatomy 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Virology (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Uso de un antagonista del receptor de glucocorticoide para la fabricacion de un medicamento para inmunoestimulacion, como, por ejemplo, la prevencion o el tratamiento de infecciones o estados infecciosos, en un sujeto mamífero de edad avanzada, un sujeto mamífero con valores DHEAS bajos en suero, un sujeto mamífero con relacion cortisol/DHEAS en suero alta, o un sujeto mamífero con recuento de neutrofilos elevado. En particular, el antagonista del receptor de glucocorticoide puede ser seleccionado dentro del grupo consistente en un derivado de dibenzopiranilo definido y/o ejemplificado en las US6329534 y WO200116128, mifepristona, y (11beta,17beta)-11-(1,3-benzodioxol-5-il)17-hidroxi-17-(1-propinil)estra-4,9-dien-3-ona.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06118587 | 2006-08-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR062229A1 true AR062229A1 (es) | 2008-10-22 |
Family
ID=37600754
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP070103470A AR062229A1 (es) | 2006-08-08 | 2007-08-07 | Uso de antagonistras del receptor de glucocorticoides para el tratamiento de estados infecciosos |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20100075936A1 (es) |
| EP (2) | EP2051705A2 (es) |
| JP (1) | JP2010500323A (es) |
| KR (1) | KR20090039775A (es) |
| CN (1) | CN101500547A (es) |
| AR (1) | AR062229A1 (es) |
| AU (1) | AU2007283604A1 (es) |
| CA (1) | CA2658016A1 (es) |
| IL (1) | IL196392A0 (es) |
| MX (1) | MX2009000950A (es) |
| TW (1) | TW200820977A (es) |
| WO (1) | WO2008017658A2 (es) |
| ZA (1) | ZA200900242B (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010052445A1 (en) | 2008-11-07 | 2010-05-14 | University Of Sheffield | Medicament and method of diagnosis |
| WO2012135274A1 (en) | 2011-03-31 | 2012-10-04 | Pop Test Cortisol Llc | Prevention of infection |
| WO2012145258A1 (en) * | 2011-04-18 | 2012-10-26 | Pop Test Cortisol Llc | Hair loss treatment |
| US8986677B2 (en) * | 2012-07-30 | 2015-03-24 | Pop Test Cortisol Llc | Therapeutic compositions and methods |
| EP3400233A4 (en) * | 2015-08-03 | 2020-02-26 | Pop Test Oncology LLC | PHARMACEUTICAL COMPOSITIONS AND METHODS |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2696934B1 (fr) * | 1992-10-20 | 1995-06-02 | Conservatoire Nal Arts Metiers | Dérivés de stéroïdes naturels 3B hydroxyles ayant des propriétés de déclenchement et de stimulation de l'immunité, composition les contenant et procédé pour les obtenir. |
| ES2092958B1 (es) * | 1995-01-10 | 1997-08-01 | Miret Lab | Procedimiento para la sintesis de tensioactivos cationicos derivados de la condensacion de acidos grasos con aminoacidos de caracter basico esterificados y su aplicacion como agentes antimicrobianos. |
| IL118974A (en) | 1995-08-17 | 2001-09-13 | Akzo Nobel Nv | History 11 - (Transformed Phenyl) - Astra - 4, 9 - Diane, their preparation and pharmaceutical preparations containing them |
| JP2000511404A (ja) * | 1996-04-09 | 2000-09-05 | ビー・テイー・ジー・インターナシヨナル・リミテツド | 神経精神、免疫又は内分泌障害を治療するための７α置換ステロイドの使用 |
| CO5180649A1 (es) | 1999-09-01 | 2002-07-30 | Abbott Lab | Antagonistas de los receptores de los glucocorticoides para el tratamiento de la diabetes para el tratamiento de la diabetes |
| US6329534B1 (en) | 1999-09-01 | 2001-12-11 | Abbott Laboratories | Glucocorticoid receptor antagonists for treatment of diabetes |
| CA2455981C (en) * | 2001-08-09 | 2012-10-09 | Joan Baptista Urgell Beltran | Use of cationic surfactants in cosmetic preparations |
| MXPA04003855A (es) * | 2001-10-25 | 2004-07-08 | Miret Lab | Uso de consevadores cationicos en productos alimenticios. |
| AU2002358540A1 (en) * | 2001-11-30 | 2003-06-10 | Solvay Pharmaceuticals Gmbh | Treatment of th2 dominated immunological disease states with progesterone receptor antagonists |
| WO2005070893A2 (en) | 2004-01-09 | 2005-08-04 | Corcept Therapeutics, Inc. | Azadecalin glucocorticoid receptor modulators |
| JP4797326B2 (ja) * | 2004-01-27 | 2011-10-19 | 大正製薬株式会社 | 生薬含有組成物 |
-
2007
- 2007-07-19 TW TW096126375A patent/TW200820977A/zh unknown
- 2007-08-06 EP EP07788248A patent/EP2051705A2/en not_active Withdrawn
- 2007-08-06 US US12/375,744 patent/US20100075936A1/en not_active Abandoned
- 2007-08-06 AU AU2007283604A patent/AU2007283604A1/en not_active Abandoned
- 2007-08-06 EP EP10159050A patent/EP2204171A1/en not_active Withdrawn
- 2007-08-06 JP JP2009523270A patent/JP2010500323A/ja active Pending
- 2007-08-06 KR KR1020097002988A patent/KR20090039775A/ko not_active Application Discontinuation
- 2007-08-06 WO PCT/EP2007/058134 patent/WO2008017658A2/en active Application Filing
- 2007-08-06 CN CNA2007800292934A patent/CN101500547A/zh active Pending
- 2007-08-06 MX MX2009000950A patent/MX2009000950A/es not_active Application Discontinuation
- 2007-08-06 CA CA002658016A patent/CA2658016A1/en not_active Abandoned
- 2007-08-07 AR ARP070103470A patent/AR062229A1/es unknown
-
2009
- 2009-01-08 IL IL196392A patent/IL196392A0/en unknown
- 2009-01-12 ZA ZA2009/00242A patent/ZA200900242B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2204171A1 (en) | 2010-07-07 |
| TW200820977A (en) | 2008-05-16 |
| KR20090039775A (ko) | 2009-04-22 |
| CN101500547A (zh) | 2009-08-05 |
| IL196392A0 (en) | 2009-09-22 |
| AU2007283604A1 (en) | 2008-02-14 |
| US20100075936A1 (en) | 2010-03-25 |
| JP2010500323A (ja) | 2010-01-07 |
| EP2051705A2 (en) | 2009-04-29 |
| MX2009000950A (es) | 2009-02-04 |
| ZA200900242B (en) | 2011-06-29 |
| WO2008017658A3 (en) | 2008-04-10 |
| CA2658016A1 (en) | 2008-02-14 |
| WO2008017658A2 (en) | 2008-02-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR062229A1 (es) | Uso de antagonistras del receptor de glucocorticoides para el tratamiento de estados infecciosos | |
| CL2008003305A1 (es) | Composicion inyectable que comprende un agente activo seleccionado de un grupo definido; al menos un polimero bioerosionable, al menos un solvente no toxico y opcionalmente uno o mas excipientes; proceso de preparacion; uso para tratar enfermedades mentales o cancer. | |
| CY1120879T1 (el) | Πολλαπλου συστατικου βιοδραστικος ενδοκολπικος δακτυλιος | |
| CL2010000989A1 (es) | Uso de 5-metil-(6s)-tetrahidrofolato, drospirenona y etinilestradiol, en ausencia de viatamina b12, para preparar un medicamento util para prolongar la reduccion del riesgo de enfermedades y malformaciones congenitas provocadas por carencias de folato seleccionadas de grupo definido (sol.div. 1130-06). | |
| CL2012002722A1 (es) | Forma farmaceutica parenteral que libera un inhibidor de aromatasa tal como anastrozol y exemestano, y un gestageno tal como levonorgestrel y gestodeno; y su uso para el tratamiento simultaneo de endometriosis y para la anticoncepcion. | |
| CL2007001724A1 (es) | Uso de un estrogeno para el tratamiento de enfermedades, condiciones o sintomas asociados con niveles deficientes de estrogenos en una mujer; composicion farmaceutica que comprende unidades de dosificacion diarias de hemidrato de estradiol > 0,75 y 1 | |
| ECSP099387A (es) | Derivados de 2,3-dihidroimidazo[1,2-c]quinazolina sustituidos de utilidad en el tratamiento de trastornos hiperproliferativos y enfermedades asociadas con la angiogénesis | |
| CL2007002018A1 (es) | Compuestos derivados de isoxazolinas sustituidas; procedimiento de preparacion; composicion farmaceutica; y uso del compuesto para el tratamiento de una enfermedad causada por un aumento en la proliferacion celular. | |
| UY28906A1 (es) | Derivados de pirimidina que son antagonistas del receptor vitronectina | |
| NO20066070L (no) | Fremgangsmate for formulering av hurtig-dispergerende former omfattende minst et fiske gelatin valgt pa grunnlag av molekylvekt | |
| DE502008002148D1 (de) | Arzneimittel umfassend wenigstens ein gestagen | |
| BR112012011282A2 (pt) | material à base de gesso incluindo um agente capaz de reter formaldeído | |
| EP1839630A3 (en) | Drapeable absorbant article | |
| CL2011003327A1 (es) | Composicion farmaceutica que comprende finafloxacina y un agente antiinflamatorio; uso en el tratamiento de infecciones oftalmicas, oticas o nasales. | |
| BRPI1011071B8 (pt) | uso de um heptapeptídeo para estimular a função genital, sexual ou reprodutiva em um mamífero | |
| AR095691A1 (es) | FORMULACIÓN DE L-5-METILTETRAHIDROFOLATO DE CALCIO AMORFO (L-5-MTHF-Ca), PROCEDIMIENTO, USO | |
| BRPI0511694A (pt) | composições de liberação controlada | |
| CL2010001471A1 (es) | Un compuestos 2-fluoro-11-(piperazin-1.il) dibenzo´1,4 tiazepina, inhibidores net y antagonista moderado d2; procedimiento de preparacion del mismo; composicion farmaceutica; y uso en el tratamiento de trastornos psiquiatricos, entre otras enfermedades.. | |
| WO2005011617A3 (en) | Transmucosal dosage forms for brain-targeted steroid chemical delivery systems | |
| GT200500122A (es) | Profarmacos de esteroides con accion androgenica | |
| BRPI0718815B8 (pt) | método de fabricação de um dispositivo de acesso vascular | |
| PA8618401A1 (es) | Prevencion y tratamiento de enfermedades cardiacas hipertensivas mediante el uso de los estrogenos selectivos 8beta-vinil-estra-1,3,5(10)-trien-3,17beta-diol y 17beta-fluor-9alfa-vinil-estra-1.3,5(10)-trien-3,16alfa-diol | |
| CL2015003014A1 (es) | Composición farmacéutica que comprende 0,5-5 mg de (11?,17?)-17-hidroxi-11-[4-(metilsulfonil)fenil]-17-(pentafluoroetil)estra-4,9-dien-3-ona; forma de dosificación oral; uso para tratar y/o prevenir una enfermedad ginecológica, tal como, fibroides en el útero, endometriosis o hemorragias menstruales excesivas. | |
| UY32005A (es) | Derivados de estratrieno que comprenden bioisósteros heterocíclicos para el anillo fenólico a | |
| GEP20115158B (en) | Use of ivabradine for obtaining medicaments intended for the treatment of endothelial dysfunction |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |